PURPOSE: To determine the activity and tolerability of SAM496A, an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), in patients with metastatic melanoma who had not received prior chemotherapy. Selected patients were offered participation in two sub-studies examining early changes in tumor metabolism with FDG-PET and changes in tumor polyamine content. PATIENTS AND METHODS: Fifteen patients with measurable metastatic melanoma, normal cardiac function, and no known CNS metastases were eligible and received SAM486A by 1-hour IV infusion daily for 5 days every 3 weeks. Response was assessed by SWOG criteria. RESULTS: No patient had a confirmed partial response. Fatigue/lethargy, myalgia and neutropenia were the main toxicities but no febrile neutropenia or grade 4 non-hematological toxicity occurred. Five patients had PET scans pre-treatment and on days 8-12 of cycle 1. No patient had reduction of tumor metabolism. Serial biopsy in one patient showed alterations in polyamines consistent with SAMDC inhibition. CONCLUSIONS: Using the present dose and schedule of administration, SAM486A does not have significant therapeutic potential in patients with metastatic melanoma.
PURPOSE: To determine the activity and tolerability of SAM496A, an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), in patients with metastatic melanoma who had not received prior chemotherapy. Selected patients were offered participation in two sub-studies examining early changes in tumor metabolism with FDG-PET and changes in tumorpolyamine content. PATIENTS AND METHODS: Fifteen patients with measurable metastatic melanoma, normal cardiac function, and no known CNS metastases were eligible and received SAM486A by 1-hour IV infusion daily for 5 days every 3 weeks. Response was assessed by SWOG criteria. RESULTS: No patient had a confirmed partial response. Fatigue/lethargy, myalgia and neutropenia were the main toxicities but no febrile neutropenia or grade 4 non-hematological toxicity occurred. Five patients had PET scans pre-treatment and on days 8-12 of cycle 1. No patient had reduction of tumor metabolism. Serial biopsy in one patient showed alterations in polyamines consistent with SAMDC inhibition. CONCLUSIONS: Using the present dose and schedule of administration, SAM486A does not have significant therapeutic potential in patients with metastatic melanoma.
Authors: Miklos Pless; Karim Belhadj; Hans D Menssen; Wolfgang Kern; Bertrand Coiffier; Jürgen Wolf; Richard Herrmann; Eckhard Thiel; Doug Bootle; Ivo Sklenar; Christian Müller; Les Choi; Carl Porter; Renaud Capdeville Journal: Clin Cancer Res Date: 2004-02-15 Impact factor: 12.531
Authors: P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: F A Eskens; G A Greim; C van Zuylen; I Wolff; L J Denis; A S Planting; F A Muskiet; J Wanders; N C Barbet; L Choi; R Capdeville; J Verweij; A R Hanauske; U Bruntsch Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo T Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel D Von Hoff; S Gail Eckhardt Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: Omar Eton; Sewa S Legha; Agop Y Bedikian; J Jack Lee; Antonio C Buzaid; Cynthia Hodges; Sigrid E Ring; Nicholas E Papadopoulos; Carl Plager; Mary Jo East; Feng Zhan; Robert S Benjamin Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: R Paridaens; D R Uges; N Barbet; L Choi; M Seeghers; W T van der Graaf; H J Groen; H Dumez; I V Buuren; F Muskiet; R Capdeville; A T Oosterom; E G de Vries Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: Shridhar Bale; Wesley Brooks; Jeremiah W Hanes; Arnold M Mahesan; Wayne C Guida; Steven E Ealick Journal: Biochemistry Date: 2009-07-14 Impact factor: 3.162
Authors: Shridhar Bale; Maria M Lopez; George I Makhatadze; Qingming Fang; Anthony E Pegg; Steven E Ealick Journal: Biochemistry Date: 2008-12-16 Impact factor: 3.162
Authors: Diane E McCloskey; Shridhar Bale; John A Secrist; Anita Tiwari; Thomas H Moss; Jacob Valiyaveettil; Wesley H Brooks; Wayne C Guida; Anthony E Pegg; Steven E Ealick Journal: J Med Chem Date: 2009-03-12 Impact factor: 7.446